There were eight canonical pathways related to the treatment of DR via KLX: mammalian target of rapamycin (mTOR) signaling, adenosine monophosphate (AMP)-activated protein kinase (AMPK) signaling, neuroinflammation signaling, peroxisome proliferator-activated receptor alpha (PPAR-α)/retinoid X receptor alpha (RXR-α) activation, apelin adipocyte signaling, type 2 diabetes mellitus (T2DM) signaling, nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) signaling, and retinoic acid receptor (RAR) activation. Here, NFKB1 is linked to type 2 diabetes mellitus.